Fabrice J.
- Country
- France
- Department
- Centre de lutte contre le cancer
Research Overview
- Phase II Open-Label Study on Lenalidomide, Tafasitamab, and Rituximab in Frontline Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older
- Phase II Evaluation of Glofitamab and Obinutuzumab in Relapsed/Refractory Lymphomas Post Anti-CD19 CAR T-Cell Therapy
- A Phase 3 Randomized Study Comparing Odronextamab and Lenalidomide Versus Rituximab and Lenalidomide in Relapsed/Refractory Follicular and Marginal Zone Lymphoma
Data & Insights
Has run more than one trial at 173 of 378 partner sites.
Specializations
B-Cell Lymphomas
Specializes in treating various forms of diffuse large B-cell lymphoma and follicular lymphoma, with particular emphasis on novel therapeutic combinations.
- Advanced treatment protocols involving rituximab-based therapies
- Bispecific antibody applications
- CAR T-cell therapy approaches
Focuses on developing innovative treatment strategies for both newly diagnosed and relapsed/refractory cases.
Specialized Lymphoma Types
Conducts research in treating distinct lymphoma variants including mantle cell lymphoma and marginal zone lymphoma.
- Novel combination therapies
- Targeted molecular treatments
- Immunotherapy approaches
Explores treatment solutions for challenging lymphoma subtypes using emerging therapeutic agents.
Advanced Therapeutic Approaches
Investigates cutting-edge treatments including monoclonal antibodies and targeted molecular therapies.
- Lenalidomide-based combinations
- Novel antibody-drug conjugates
- Immunotherapy optimization
Focuses on developing personalized treatment strategies for various lymphoma presentations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.